Valvular Aortic Valve

Structural heart disease

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to...

Dr. Juan Manuel Pérez - 27 November, 2025

Learn More

Structural heart disease

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to...

Dr. Juan Manuel Pérez - 26 November, 2025

Learn More

Structural heart disease

Transradial Aortic Valvuloplasty: Is Minimalism Worth It?

Balloon aortic valvuloplasty (BAV) has historically been used either as a bridge strategy, an assessment tool, or...

Dr. Omar Tupayachi - 19 November, 2025

Learn More

Structural heart disease

TCT 2025 | SUMMIT-MAC: Transcatheter Mitral Valve Replacement with the Tendyne System in Patients with Severe Annular Calcification

The prospective, multicenter SUMMIT-MAC study evaluated the safety and efficacy of transcatheter mitral valve replacement (TMVR) using...

Dr. Juan Manuel Pérez - 29 October, 2025

Learn More

Structural Heart Disease

TCT 2025 | PREVUE-VALVE: Prevalence of Valvular Heart Disease in Elderly US Patients

The PREVUE-VALVE study was designed to determine the true prevalence and demographic determinants of valvular heart disease...

Dr. Juan Manuel Pérez - 29 October, 2025

Learn More

Mitral valve

TCT 2025 | Transcatheter Mitral Valve Replacement with SAPIEN M3: ENCIRCLE 1-Year Outcomes

Transcatheter mitral valve replacement (TMVR) is an emerging option for patients with symptomatic mitral regurgitation (MR) who...

Dr. Juan Manuel Pérez - 29 October, 2025

Learn More

Structural heart disease

TCT 2025 | PARTNER 3 Trial 7-Year Outcomes: TAVR vs SAVR in Low-Risk Patients

The randomized PARTNER 3, which initially showed TAVR superiority when using the SAPIEN 3 valve over SAVR...

Dr. Juan Manuel Pérez - 29 October, 2025

Learn More

Structural heart disease

Impact of Amyloidosis on Outcomes After TAVI

Cardiac amyloidosis (CA) is a systemic and progressive disease characterized by the accumulation of misfolded proteins in...

Dr. Juan Manuel Pérez - 22 October, 2025

Learn More

Valvular Aortic Valve

Is it really necessary to monitor all patients after TAVR?

Is it really necessary to monitor all patients after TAVR?

Transradial Aortic Valvuloplasty: Is Minimalism Worth It?

TCT 2025 | SUMMIT-MAC: Transcatheter Mitral Valve Replacement with the Tendyne System in Patients with Severe Annular Calcification

TCT 2025 | PREVUE-VALVE: Prevalence of Valvular Heart Disease in Elderly US Patients

TCT 2025 | Transcatheter Mitral Valve Replacement with SAPIEN M3: ENCIRCLE 1-Year Outcomes

TCT 2025 | PARTNER 3 Trial 7-Year Outcomes: TAVR vs SAVR in Low-Risk Patients

Impact of Amyloidosis on Outcomes After TAVI

Last News

Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

Is it really necessary to monitor all patients after TAVR?

Is it really necessary to monitor all patients after TAVR?

Institutional News

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

Watch Again: SELUTION – Sirolimus-Eluting Balloon for De Novo Coronary Lesions – New Evidence and Clinical Perspectives

25/11 – SOLACI Webinar: Pulmonary Embolism in 2025 – Risk Stratification and Novel Therapeutic Approaches

Access